Gastroretentive Drug Delivery System

Authors

  • Mr. Wasim Fayaz
  • Pankaj Chasta Assistant Professor, Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan, India-312901.
  • Tawseef Hassan Sheikh Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan, India-312901.
  • Muddasir Ahmad Rather Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan, India-312901.
  • Aqib Hussain Kumar Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan, India-312901.
  • Aadil Mustafa Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan, India-312901.

Abstract

Gastroretentive dosage form (GRDF) has played an important role in the past few periods in improving the limitation of most predictable and oral controlled release drug delivery system related to fast gastricemptying time. GRDF system can be defined as a system which remains in the stomach for an adequate time interval against all the physiological barriers, and releases active moiety in a well-ordered manner. This paper gives an overview of the parameters affecting gastric emptying as well as on the main thoughts used to design pharmaceutical dosage forms with prolonged gastric residence times. In particular, bioadhesive, size-increasing, and floating drug delivery systems are presented, and their major advantages and limitations are discussed. Both single and multiple-unit dosage forms with dual working arrangements are reviewed. Dual-working classifications are more efficient than the traditional systems.

References

1. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. Int J Pharma 1996; 136: 117-39.
2. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res 2008; 7(3): 1055-66.
3. Pawar VK, Kansal S, Garg G et al. Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. Drug Delivery 2011; 18: 97.
4. Nayak AK, Maji R, Das B. Gastroretentive drug delivery system: A review. Asian Journal of Pharmaceutical and Clinical Research 2010; 3: 1.
5. Majethiya Karan A, Patel MR. Review on gastro retentive drug delivery system. International Journal of Universal Pharmacy and Bio Sciences Jan-Feb 2013; 2(1): 110-25.
6. Singh BN, Kim. Floating drug delivery systems: An approach to controlled drug delivery via gastric retention. J Control Release 2000; 63: 235-39.
7. Ali J, Arora S, Khar RK. Floating drug delivery system: A review; AAPS Pharm Sci Tech 2005; 06(03): E372-E390.
8. Yie W, Chein. Novel Drug Delivery System, 2nd ed. New York: Marcel Dekker Inc 1992; 1-3.
9. Garg S, Sharma S. Gastroretentive drug delivery systems. Pharmatech 2003; 160-66.
10. Vedha H. The recent developments on gastric floating drug delivery systems: An overview. Int Journal Pharmtech Res 2010; 2(1): 524-34.
11. Chien Yie W. Concepts and System Design for Rate Controlled Drug Delivery in Novel Drug Delivery System, 2nd Edn., New York: Marcell Dekker Inc 1992.
12. Joseph R, Robinson, Vincent H et al. Controlled Drug Delivery, Fundamentals and Applications, 2nd Edition, Revised and Expanded. New York: Marcell. Dekker Inc 2009.
13. El-Zahaby SA, Kassem AA, El-Kamel AH. Formulation and in vitro evaluation of size expanding gastroretentive systems of levofloxacin hemihydrates. Int J Pharm 2014 Jan; 464: 10-18.
14. Kumar N, Niranjan SK, Irchhaiya R et al. Novel approaches of floating drug delivery system: a review. Int J Pharm Res Scholars 2012; 1(4): 96-111.
15. Chavanpatil MD, Jain P, Chaudhari S et al. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for Ofloxacin. Int J Pharm 2006 Mar; 316: 86-92.
16. Birajdar SM. Development and evaluation of floatingmucoadhesive dipyridamole tablet. Int J Pharmamedix
India 2013 Apr; 1(2): 233-57.
17. Patel AK, Patel VM. A review: Gastroretentive drug delivery systems and its rational in peptic ulcer treatment. J Pharm Sci Bioscientific Res 2012 Aug; 2(4): 179-88.
18. Rao GK, Mandapalli PK, Manthri R et al. Development and in vivo evaluation of gastroretentive delivery systems for cefuroxime axetil. Saudi Pharm J 2012 Jan; 21: 53-59.
19. Shakya R, Thapa P, Saha RN. In vitro and in vivo evaluation of gastroretentive floating drug delivery system of ofloxacin. Asian J Pharm Sci 2013 Jun; 8: 191-98.
20. Vo AQ, Feng X, Morott J T et al. A novel floating controlled release drug delivery system prepared by hot-melt extrusion. Eur J Pharm Biopharm 2015 Nov; 98: 108-21.
21. Mantry S, Kumar GN, Reddy K et al. Formulation and evaluation of bio adhesive floating Ondasetron tablet. Int J Pharm Bio Sci 2013 Oct; 4(4): 288-95.
22. Sandhan S, Singh R, Kakar S. Gastroretentive drug delivery systems- a review. Afr J Pharm Pharmcol 2015 Apr; 9(12): 405-17.
23. Jagdale SC, Patil SA, Kucheka BS. Design development and evaluation of floating tablets of tapentadol hydrochloride using chitosan. Asian J Pharm Clin Res 2012 Sep; 5(4): 163-68.
24. Nasa P, Mahant S, Sharma D. Floating system: a novel approach toward gastro retentive drug delivery systems. Int J Pharm Pharm Sci 2010 Apr; 2(3): 2-7.
25. Deshpande RD, Keerthy HS, Gowda DV et al. Development of non-effervescent low density floating tablets of cefpodoxime proxetil. Int J Pharm Res Scholars 2014 Jul; 3(3): 69-77.
26. Patel T, Talele A, Kumar S et al. Formulation optimization and evaluation of raft forming tablet of Nizatidine. Indo Am J Pharm Res 2015 Mar; 5(3): 1173-90.
27. Sharma D, Sharma A. Gastroretentive drug delivery systems: a mini review. Asian Pacific Journal of Health Sciences 2014; 1(2): 80-89.
28. Mane SS, Kamble MS, Mane OR et al. Optimization of floating osmotic drug delivery system of diltiazem hydrochloride using 32 factorial design. Indo Am J Pharm Res 2013 Jun; 3(6): 4585-93.
29. Bardonnet PL, Faivre V, Pugh WJ et al. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J Controlled Release 2006 Jan; 111: 1-18.
30. Fujimori J, Machida Y, Tanaka S et al. Effect of magnetically controlled gastric residence of sustained release tablets on bioavailability of acetaminophen. Int J Pharm 1995; 119: 47-55.
31. Yeong CH, Abdullah BJJ, Hoong NK et al. Production and first use of 153 SmCl3-ion exchange resin capsule formulation for assessing gastrointestinal motility. Appl Radiat Isot 2011 Dec; 70: 450-55.
32. Dubernet C. Syste`mes a` liberation gastrique prolonge`e. In: Falson-Rieg F, Faivre V, Pirot F, editors. Novelles formes me`dicamenteuses. Editions Me`dicales Internationales. Editions TEC and DOC. Cachan 2004; 119-33.
33. Arrora S, Ali J, Khar RK et al. Floating drug delivery systems: A review. AAPS Pharm Sci Tech 2005; 6(3): 372-90.
34. El-Kamel AH, Sokar MS, Al Gamal SS et al. Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharm 2001; 220: 13-21.
35. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing: Pharmatech 2003: 160-66.
36. Khosla R, Feely LC, Davis SS. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int J Pharm 1989; 53: 107-17.
37. Mojaverian P, Vlasses PH, Kellner PE et al. Effects of gender, posture and age on gastric residence time of an indigestible solid: Pharmaceutical considerations. Pharm Res 1988; 10: 639-44.

Downloads

Published

2018-10-27

How to Cite

Fayaz, M. W., Chasta, P., Sheikh, T. H., Rather, M. A., Kumar, A. H., & Mustafa, A. (2018). Gastroretentive Drug Delivery System. Journal of Drug Discovery and Development ( ISSN:2581-6861), 2(1), 11-17. Retrieved from https://medicaljournalshouse.com/index.php/JDrug-Discovery-Development/article/view/59

Issue

Vol. 2 No. 1 (2018): Journal of Drug Discovery and Development

Section

Research Article

License

We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________

Important

(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.

(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.

(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.